Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-498

Hi Reg,

I have to say CEO Itescu got my attention when he said - loud & clear - at the AGM (when asked did the Board intend that there be dividends for ordinary shareholders) "Of course". Others may be able to confirm that my hearing isn't completely shot.

So, I don't think it's as simple as just one number. I'd like to know, for example, what kind of dividend policy the Board thought it could support in future years. And yes, I know it's just a tad early for that discussion.

Because I really, really don't want to have an all or nothing plan for this stock. I want something more fungible for my family SMSF, and I think Mesoblast is going to be a prime candidate for flexible, manageable growth & income.

But, if you want to talk M&A, it's whatever number CEO Itescu says represents fully-emerged value in the US & EU markets from all of the currently identified indications supported by at least a P1 study.

There's a question for the AGM after-party. Oysters & beer, remember.

Cheers
Have a good night
GLTA(LT)H